3
Oct
2018

Overcoming a Bad Job Market, Finding a Path in Biotech: Sabah Oney on The Long Run

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Arch Bets $50M on Vilya, Baker Lab Spinout to Make Targeted, Oral Peptide Drugs
Writing in the Language of DNA: Kevin Ness on The Long Run
Blazing a New Trail in Psychiatry & Women’s Health: Jeff Jonas on The Long Run
Life of a Scientific Entrepreneur: Bob Langer of MIT on The Long Run